Medincell's Stock Rebounds 4% Days Before Annual Results
The biotech company from Montpellier is moving forward on the eve of its annual financial report. The stock is among the top performers in the SBF 120, in a generally positive Parisian market. This rebound comes after a sharp decline in the previous session.
Medincell Moves Above Its Moving Averages in a Supportive Parisian Market
Medincell's stock gains 4.29% to €27.7, while the SBF 120 advances by 0.91% and the CAC 40 increases by 0.97%. The stock ranks among the highest risers of the broader index, trailing behind STMicroelectronics, Soitec, Eramet, and LVMH. The rebound mitigates some of the more than 3% decline recorded the day before, as the financial milestone approaches. The price returns to its 20-day moving average at €27.15, slightly surpassing it by 0.26%.
It also significantly exceeds the 50-day moving average (€25.46) by nearly 7%, confirming a medium-term upward trend. A Relative Strength Index (RSI) at 50 indicates a balanced market without directional excess. The annual performance stands at over 70%, with a three-month gain reaching 19.49%.
Annual Results for 2025-2026 Expected on June 16 as Next Financial Milestone
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The Montpellier-based biotech is set to publish its annual results (for the fiscal year April 2025-March 2026) on June 16, 2026, which is next Tuesday. This event is the next identified catalyst in the company's financial calendar. The stock approaches this date after recent progress in its European file, with the EMA's acceptance of the marketing authorization application for olanzapine LAI developed with Teva, announced on May 22.
From a technical perspective, the resistance at €28.72, already tested and briefly surpassed at the end of May before falling back below this level at the beginning of June, remains the reference point as the publication approaches. The support at €24.52 marks the lower consolidation zone. The session on June 16 will decide the recent technical dynamic.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
